Alumis Inc.ALMS
Immunology14 cited findings · profile updated 2026-08-25
23.03 USDnot live — refreshed daily
About Alumis Inc.
Alumis Inc. is focused on immunology. The company's drug, envudeucitinib, is being investigated in the ONWARD3 trial, where it demonstrated a PASI 100 response rate of 54% and a PASI 90 response rate of 75%. In the ONWARD program, envudeucitinib achieved a PASI 90 of 66% and a PASI 100 of 47%. For envudeucitinib in the ONWARD3 trial, 80% of patients sustained a PASI 100 response and 90% sustained a PASI 90 response.
Alumis Inc. anticipates topline data for envudeucitinib in the LUMUS Phase 2b trial in Q3 2026. A New Drug Application submission for envudeucitinib is expected in Q4 2026, with a submission in the United States anticipated in the fourth quarter of this year.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| PASI 100 response rate | 54 % (envudeucitinib (ONWARD3)) | ALUMIS INC. — SEC 8-K (2026-08-13), p.1 |
| PASI 90 response rate | 75 % (envudeucitinib (ONWARD3)) | ALUMIS INC. — SEC 8-K (2026-08-13), p.1 |
| PASI 100 response sustained | 80 % (envudeucitinib (ONWARD3)) | ALUMIS INC. — SEC 8-K (2026-08-10), p.1 |
| PASI 90 response sustained | 90 % (envudeucitinib (ONWARD3)) | ALUMIS INC. — SEC 8-K (2026-08-10), p.1 |
| PASI 90 | 66 % (envudeucitinib (ONWARD program)) | ALUMIS INC. — SEC 8-K (2026-08-10), p.1 |
| PASI 100 | 47 % (envudeucitinib (ONWARD program)) | ALUMIS INC. — SEC 8-K (2026-08-10), p.1 |
Key projects
- envudeucitinib
A New Drug Application submission for envudeucitinib is expected in Q4 2026.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Immunology research library →